Aging Populations Will Boost Personalized Oncology While Regulatory Risks Persist
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
29 May 25
Updated
08 Aug 25
AnalystHighTarget's Fair Value
US$4.00
21.8% overvalued intrinsic discount08 Aug
US$4.87
1Y
34.9%7D
51.2%